PCSK9变异、低密度脂蛋白胆固醇与神经认知障碍:REGARDS研究
在REGARDS研究的黑人参与者中,比较携带PCSK9功能丧失变异者与未携带者的神经认知障碍和认知下降情况。结果显示,终生暴露于较低PCSK9水平和累积暴露于较低LDL-C水平与神经认知效应无关。
要点
- PCSK9功能丧失变异与神经认知障碍无显著关联。
- LDL-C每降低20 mg/dL,神经认知障碍的比值比接近1。
- 认知下降模式在携带者与非携带者间相似。
核心结论
- 终生暴露于低PCSK9水平和累积暴露于较低LDL-C水平与黑人神经认知效应无关。
研究设计与样本
- 神经认知测试包括CERAD成套测验和六项筛查器,纵向随访。
- 神经认知障碍定义为CERAD两项或三项评分低于年龄、性别和教育分层均值≥1.5 SD,或SIS评分<5。
- 神经认知下降通过个体测试的标准化连续评分评估。
主要发现
- 平均年龄64岁(SD 9),女性占62%。
- 任何评估时神经认知障碍患病率:CERAD定义6.3%,SIS定义15.4%。
- 携带者 vs 非携带者的神经认知障碍调整比值比:CERAD 1.11(95%CI 0.58-2.13),SIS 0.89(95%CI 0.61-1.30)。
- 5.6年(范围0.1-9.1)随访期间,个体神经认知测试评分标准化平均差异范围0.07(95%CI -0.06至0.20)至-0.07(95%CI -0.18至0.05)。
- 神经认知下降模式在携带者与非携带者间相似(所有P>0.10)。
临床怎么用
- 对于黑人患者,PCSK9功能丧失变异及较低LDL-C水平未显示与神经认知障碍或下降相关。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Despite concerns about adverse neurocognitive events raised by prior trials, pharmacological PCSK9 (proprotein convertase subtilisin/kexin type-9) inhibition was not associated with neurocognitive effects in a recent phase 3 randomized trial. PCSK9 loss-of-function (LOF) variants that result in lifelong exposure to lower levels of low-density lipoprotein cholesterol can provide information on the potential long-term effects of lower low-density lipoprotein cholesterol on neurocognitive impairment and decline. METHODS: We investigated the association between PCSK9 LOF variants and neurocognitive impairment and decline among black REGARDS study (Reasons for Geographic and Racial Differences in Stroke) participants with (n=241) and without (n=10 454) C697X or Y142X LOF variants. Neurocognitive tests included the Consortium to Establish a Registry for Alzheimer's Disease (CERAD) battery (Word List Learning, World List Delayed Recall, Semantic Animal Fluency) and Six-Item Screener (SIS) assessments, administered longitudinally during follow-up. Neurocognitive impairment was defined as a score ≥1.5 SD below age, sex, and education-based stratum-specific means on 2 or 3 CERAD assessments or, separately, a score <5 on any SIS assessment at baseline or during follow-up. Neurocognitive decline was assessed using standardized continuous scores on individual neurocognitive tests. RESULTS: The mean sample age was 64 years (SD, 9), 62% were women, and the prevalence of neurocognitive impairment at any assessment was 6.3% by CERAD and 15.4% by SIS definitions. Adjusted odds ratios for neurocognitive impairment for participants with versus without PCSK9 LOF variants were 1.11 (95% confidence interval [CI], 0.58-2.13) using the CERAD battery and 0.89 (95% CI, 0.61-1.30) using the SIS assessment. Standardized average differences in individual neurocognitive assessment scores over the 5.6-year (range, 0.1-9.1) study period ranged between 0.07 (95% CI, -0.06 to 0.20) and -0.07 (95% CI, -0.18 to 0.05) among participants with versus without PCSK9 LOF variants. Patterns of neurocognitive decline were similar between participants with and without PCSK9 LOF variants (all P>0.10). Odds ratios for neurocognitive impairment per 20 mg/dL low-density lipoprotein cholesterol decrements were 1.02 (95% CI, 0.96-1.08) and 0.99 (95% CI, 0.95-1.02) for the CERAD and SIS definitions of impairment, respectively. CONCLUSIONS: These results suggest that lifelong exposure to low PCSK9 levels and cumulative exposure to lower levels of low-density lipoprotein cholesterol are not associated with neurocognitive effects in blacks.
引用
- Mefford MT, Rosenson RS, Cushman M, et al. PCSK9 Variants, Low-Density Lipoprotein Cholesterol, and Neurocognitive Impairment: Reasons for Geographic and Racial Differences in Stroke Study (REGARDS). Circulation. 2017. PMID: 29146683. doi:10.1161/CIRCULATIONAHA.117.029785
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。